Search Results for "Pain"
Search again or select article below to purchase. Single article price: $45. Order 3 or more at one time and receive a 10% discount.
Sort by relevance | Sort by date
Searched for Pain. Results 161 to 170 of 890 total matches.

Expanded Table: Some Vaccines for Travelers (online only)

   
The Medical Letter on Drugs and Therapeutics • Nov 19, 2018  (Issue 1560)
▶ Injection-site pain is common; swelling and erythema can occur ▶ Mild systemic complaints ...
View the Expanded Table: Some Vaccines for Travelers
Med Lett Drugs Ther. 2018 Nov 19;60(1560):e192-4 |  Show IntroductionHide Introduction

Adult Immunization

   
The Medical Letter on Drugs and Therapeutics • Oct 17, 2022  (Issue 1661)
with administration of Td or Tdap, but they are usually mild. Fever and injection-site pain have been more frequent ...
The Advisory Committee on Immunization Practices (ACIP) recommends use of certain vaccines in adults residing in the US. Routine childhood immunization has reduced the overall incidence of some of these vaccine-preventable diseases, but many adults remain susceptible. Recommendations for vaccination against COVID-19, seasonal influenza, and monkeypox and vaccination of travelers have been reviewed separately.
Med Lett Drugs Ther. 2022 Oct 17;64(1661):161-8 |  Show IntroductionHide Introduction

Delgocitinib Cream (Anzupgo) for Chronic Hand Eczema

   
The Medical Letter on Drugs and Therapeutics • Oct 13, 2025  (Issue 1739)
, patients may experience pain, erythema, edema, scaling, vesicles, hyperkeratosis, fissures ...
The FDA has approved a 2% cream formulation of delgocitinib (Anzupgo – Leo), a Janus kinase (JAK) inhibitor, for treatment of moderate to severe chronic hand eczema (dermatitis) in adults who had an inadequate response to or are unable to use topical corticosteroids. Delgocitinib is the first drug to be approved in the US for this indication. Ruxolitinib, another JAK inhibitor, is available in a 1.5% cream formulation (Opzelura) for treatment of mild to moderate atopic dermatitis in patients ≥2 years old.
Med Lett Drugs Ther. 2025 Oct 13;67(1739):163-5   doi:10.58347/tml.2025.1739b |  Show IntroductionHide Introduction

Fezolinetant (Veozah) for Menopausal Vasomotor Symptoms

   
The Medical Letter on Drugs and Therapeutics • Jun 26, 2023  (Issue 1679)
significantly greater with fezolinetant than with placebo. Adverse Effects: Abdominal pain, diarrhea, insomnia ...
Fezolinetant (Veozah – Astellas), a first-in-class neurokinin 3 (NK3) receptor antagonist, has been approved by the FDA for treatment of moderate to severe vasomotor symptoms (VMS) due to menopause. It is the second nonhormonal treatment to be approved in the US for this indication; a low-dose formulation of the selective serotonin reuptake inhibitor (SSRI) paroxetine mesylate (Brisdelle) was approved in 2013.
Med Lett Drugs Ther. 2023 Jun 26;65(1679):97-9   doi:10.58347/tml.2023.1679a |  Show IntroductionHide Introduction

Acetaminophen, Nsaids and Alcohol

   
The Medical Letter on Drugs and Therapeutics • Jun 21, 1996  (Issue 977)
— Mild to moderate pain usually responds to 650 mg of acetaminophen; more severe pain is more likely ...
An advertising war between manufacturers of over-the-counter (OTC) analgesics has led some patients to ask their physicians about the safety of taking these products if they also drink alcohol.
Med Lett Drugs Ther. 1996 Jun 21;38(977):55-6 |  Show IntroductionHide Introduction

Topical Penciclovir for Herpes Labialis

   
The Medical Letter on Drugs and Therapeutics • Jun 20, 1997  (Issue 1003)
daily) for four days. One trial in 1,573 treated patients found that the time to loss of pain was 3.5 ...
Penciclovir 1% cream (Denavir - SmithKline Beecham) has been approved by the US Food and Drug Administration (FDA) for treatment of recurrent orolabial herpes simplex virus (HSV) infections in adults. Acyclovir (Zovirax) is also available in a topical formulation for treatment of herpes simplex infections, but is approved by the FDA only for use in immunocompromised patients. Oral drugs approved for treatment of some herpes simplex infections, but not recurrent orolabial infections, include acyclovir, valacyclovir (Valtrex) and famciclovir (Famvir), which is rapidly hydrolyzed to...
Med Lett Drugs Ther. 1997 Jun 20;39(1003):57-8 |  Show IntroductionHide Introduction

In Brief: Propofol Revisited

   
The Medical Letter on Drugs and Therapeutics • Oct 17, 2011  (Issue 1375)
commonly used parenteral anesthetic in the US.2 The main problems with its use have been pain ...
A reader has asked us to review the use of propofol (Diprivan, and others) as a sedative agent for brief procedures, such as colonoscopy.First marketed more than 20 years ago,1 propofol has a rapid onset of action (patients usually lose consciousness in less then one minute) and a short duration of action with a rapid recovery (3-5 minutes) that makes it highly suitable for brief ambulatory procedures. Propofol is now the most commonly used parenteral anesthetic in the US.2 The main problems with its use have been pain on injection and bacterial contamination, both related to its lipid...
Med Lett Drugs Ther. 2011 Oct 17;53(1375):84 |  Show IntroductionHide Introduction

In Brief: Pancreatitis with Eluxadoline (Viberzi) in Patients without a Gallbladder

   
The Medical Letter on Drugs and Therapeutics • Apr 24, 2017  (Issue 1519)
abdominal pain and vomiting shortly after taking the first dose. At least 48 of the cases occurred after ...
The FDA has warned that eluxadoline (Viberzi – Allergan), a mu-opioid receptor agonist and delta-opioid receptor antagonist approved in 2015 for treatment of irritable bowel syndrome with diarrhea (IBS-D),1 should not be used in patients without a gallbladder because of an increased risk of serious pancreatitis.2As of February 2017, the FDA had received reports of 118 cases of serious, nonfatal pancreatitis and 2 deaths associated with use of eluxadoline. Both deaths occurred in patients without a gallbladder who developed severe abdominal pain and vomiting shortly after taking the first...
Med Lett Drugs Ther. 2017 Apr 24;59(1519):70 |  Show IntroductionHide Introduction

In Brief: Melphalan (Hepzato) for Uveal Melanoma (online only)

   
The Medical Letter on Drugs and Therapeutics • Sep 04, 2023  (Issue 1684)
, musculoskeletal pain, dyspnea, and abdominal pain were reported with use of melphalan. The label of Hepzato ...
...
Med Lett Drugs Ther. 2023 Sep 4;65(1684):e148   doi:10.58347/tml.2023.1684d |  Show IntroductionHide Introduction

Comparison Table: Some Topical Drugs for Rosacea (online only)

   
The Medical Letter on Drugs and Therapeutics • Feb 05, 2024  (Issue 1695)
peroxide – Epsolay (Galderma) 5% cream Yes No Pain, erythema, pruritus, edema, dryness, stinging/ burning ...
View the Comparison Table: Some Topical Drugs for Rosacea
Med Lett Drugs Ther. 2024 Feb 5;66(1695):e22   doi:10.58347/tml.2024.1695c |  Show IntroductionHide Introduction